
Synthetica Pioneering Secures Series A Funding to Accelerate Oncolytic Bacterial Therapy for Solid Tumors
Shenzhen Synthetica Pioneering Co., Ltd. has successfully concluded a Series A funding round, raising significant capital to propel its innovative oncolytic bacterial therapy into clinical trials. This funding milestone, spearheaded by prominent investors including Boehringer Ingelheim Venture Fund and Temasek, along with contributions from Lenovo Capital, Fosun Health Capital, and ATLATL Summer Fund, underscores the…